Spotlight On... Chinese Nobel laureate Tu eyes clinical trials for lupus candidate from artemisinin; Sun completes sale of 2 Ranbaxy divisions; Lupin launches diabetes drug in U.S.; and more...

An application by a team led by pharmacologist and Nobel Prize laureate Tu Youyou for clinical trials using antimalarial drug artemisinin to treat autoimmune inflammatory disease lupus is under review by China FDA, China.org.cn said. The online news portal said a source at the CFDA confirmed the application this week. Last year, Tu was awarded the Nobel Prize in physiology or medicine, the first Chinese citizen to win in the sciences, for her work on using a traditional Chinese medicine, artemisinin, to develop the country's first modern drug. Her team has worked with artemisinin on autoimmune diseases for the past decade, China.org.cn said, adding that in May last year, "a team from Shanghai Institute of Materia Medica obtained a permit for similar tests of a water-soluble artemisinin derivative to treat lupus." Report

> Sun Pharmaceutical said it has completed the sale of two divisions from its Ranbaxy acquisition to Strides Shasun. Report

> New Delhi-based Lupin has launched its Metformin HCI diabetes treatment in the United States. Report

> India's pharmaceutical market is expected to be worth $55 billion in 2020, according to U.S. researcher GlobalData. Report

> Specialised Therapeutics Asia said it will supply and distribute the myeloma treatment APLIDIN in Southeast Asia, Australia and New Zealand. Release

> Australia's Prescient Therapeutics officials said they believe they can increase the number of women who respond positively to chemotherapy to treat breast cancer by combining the treatment with the company's drug candidate PTX-200. Report

Suggested Articles

CureVac was granted a patent by the U.S. Patent and Trademark Office for its manufacturing process for producing RNA.

The WHO stopped classifying Zika as an emergency in late 2016, but Takeda has pressed ahead with its program, winning an FDA fast-track designation.

After failing a phase 2 in solid-organ transplant patients, the CMV vaccine failed in hematopoietic cell transplant recipients too.